A new protein targeted treatment for B-cell lymphoma
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Assessing whether blocking a protein's activity could improve survival and reduce side effects.
Creating antibodies in the lab to treat diffuse midline gliomas and testing their effectiveness.
Understanding how proteins act inside acute myeloid leukaemia cells, to find new drug targets.
Finding why immunotherapy doesn't work for some children with sarcoma tumours.
Testing nanoparticles as a way of getting drugs where they are needed for acute myeloid leukaemia.
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.
Looking into whether survivors of childhood cancer are at risk of severe infections.
Developing more effective treatments for patients who have a low chance of survival, while reducing treatment and side effects for other patients.
Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene